ESPR May 2024 3.000 call
| Previous close | 0.0800 |
| Open | 0.1000 |
| Bid | 0.0500 |
| Ask | 0.1000 |
| Strike | 3.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.0500 - 0.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | 2.91k |
- GuruFocus.com
Esperion Therapeutics Inc (ESPR) Surpasses Q1 Revenue Forecasts with a 467% Increase
Significant Growth and FDA Approvals Propel Performance
ZacksEsperion Therapeutics (ESPR) Q1 Earnings and Revenues Beat Estimates
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 525% and 159.32%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireEsperion Reports First Quarter 2024 Financial Results
– Q1 Total Revenue Grew 467% Y/Y to $137.7 Million, Reflecting Strong Growth Globally – – Q1 U.S. Net Product Revenue Grew 46% Y/Y to $24.8 Million – – Q1 Retail Prescription Equivalents Grew 43% Y/Y and 6% Q/Q, Increased Momentum from Label Expansions Expected Throughout 2024 – – Received U.S. FDA Approval of Broad New Label Expansions for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet, Becoming the First LDL-C Lowering Non-Statins to Prevent Heart Attacks
